SCHEMBL2473963

SCHEMBL2473963

CCc1ccc(CCNC(=O)C2(Cc3ccccc3)CCN(C(=O)Cc3ccc(F)cc3)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HSD11B1 P28845 2/20 0.43
KMT2A Q03164 4/20 0.42
PLAAT3 P53816 1/20 0.42
PLAAT5 Q96KN8 1/20 0.42
PLAAT2 Q9NWW9 1/20 0.42
PLAAT4 Q9UL19 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
LTA4H P09960 1/20 0.42
EPHX2 P34913 1/20 0.42
MEN1 O00255 3/20 0.42
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
CCR3 P51677 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2470205 0.95 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2KDM4EHSD11B1KMT2A
SCHEMBL2470199 0.92 GFER (0.50) ALDH1A1SMN1; SMN2KMT2APLAAT3PLAAT5
SCHEMBL2467872 0.90 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2KDM4EHSD11B1KMT2A
SCHEMBL2469275 0.89 MAPT (0.54) ALDH1A1SMN1; SMN2KMT2APLAAT3PLAAT5
SCHEMBL2472974 0.88 KMT2A (0.57) ALDH1A1SMN1; SMN2KMT2APLAAT3PLAAT5
SCHEMBL2471698 0.87 MEN1 (0.48) ALDH1A1SMN1; SMN2KDM4EKMT2ARAB9A
SCHEMBL2471735 0.87 NPC1 (0.49) ALDH1A1SMN1; SMN2KMT2ANPC1EPHX2
SCHEMBL2472142 0.87 GFER (0.55) SMN1; SMN2KMT2APLAAT3PLAAT5PLAAT2
SCHEMBL2469409 0.87 GFER (0.55) SMN1; SMN2KMT2APLAAT3PLAAT5PLAAT2
SCHEMBL2467982 0.85 MEN1 (0.42) ALDH1A1SMN1; SMN2KDM4EKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 ALDH1A1 3941/4885SMN1; SMN2 4032/4885KDM4E 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.